“We are grateful to the family who made it possible to provide expanded access to zervimesine for people who were in the Phase 2 DLB study,” stated Lisa Ricciardi, president and CEO of Cognition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback